Iclusig

A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Iclusig blocks BCR-ABL and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Iclusig is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Also called ponatinib hydrochloride.